Noninvasive Positive Pressure Ventilation versus High-Flow Nasal Cannula for Chronic Obstructive Pulmonary Disease: An Updated Narrative Review
Yuting Wang,Yan Liu,Kan Liu,Yuan He,Hui Ding
DOI: https://doi.org/10.2147/copd.s487994
2024-11-10
International Journal of COPD
Abstract:Yuting Wang, &ast Yan Liu, &ast Kan Liu, Yuan He, Hui Ding Department of Pulmonary and Critical Care Medicine, Yixing People's Hospital Affiliated to Jiangsu University, Yixing, Jiangsu Province, 214200, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hui Ding, Email Chronic obstructive pulmonary disease (COPD) is one of the most common clinical respiratory illnesses, defined by permanent pathological deterioration that leads to respiratory failure. Regarding COPD treatment, oxygen therapy is very important. Non-invasive positive pressure ventilation (NPPV) is a technique for non-invasive mechanical ventilation that enables patients to get positive pressure support without the need of an artificial airway. Instead, it merely employs the mask by covering the mouth and nose, or simply the nose of patients. NPPV has been shown to be beneficial for COPD patients experiencing respiratory failure. High-flow nasal cannula (HFNC) oxygen therapy shows some advantages, including the reduction of anatomical dead space, the prompt correction of low oxygen levels as well as the improvement of patients' tolerance. Owing to its continuous progress, ventilation technology strongly improves COPD treatment. In this study, the authors analyze the application of NPPV and HFNC in COPD so as to provide recommendations for mechanical ventilation treatment. Keywords: chronic obstructive pulmonary disease, high flow nasal cannula, non-invasive positive pressure ventilation, respiratory failure Chronic obstructive pulmonary disease (COPD) is a common respiratory condition with high morbidity and mortality rates, and has become a major cause of death worldwide. 1 Moreover, it is associated with significant economic and societal burdens. Persistent airflow limitation and changes in the respiratory tract caused by COPD lead to symptoms including dyspnea and cough. Acute exacerbation of COPD (AECOPD) describes the sudden worsening of symptoms, such as dyspnea, cough, or phlegm, within a short period, for which a basic medication regimen is required; nevertheless, prognosis may be poor. Respiratory failure is a common and serious complication of AECOPD that impairs effective gas exchange. Patients with type II respiratory failure and hypercapnia have a higher risk for mortality. Currently, drug therapy and respiratory support options, such as conventional oxygen therapy, high-flow nasal cannula (HFNC), noninvasive positive pressure ventilation (NPPV), and invasive positive pressure ventilation, 2 are commonly used to treat patients with AECOPD. With the assistance of accessories, such as nasal masks, mouth and nose masks, or full-face masks that connect the patient to the ventilator, NPPV can provide positive pressure-assisted ventilation without invasive procedures. 3,4 For patients with AECOPD and acute respiratory failure, NPPV provides good respiratory support because it is not only beneficial for enhancing oxygenation and correcting acute respiratory acidosis, but also helpful in regulating pH and reducing the partial pressure of carbon dioxide ( Pa CO 2 ) to control respiratory failure. In addition, it reduces the workload of the respiratory muscles, alleviates dyspnea, and provides assistance in COPD treatment. According to some studies, NPPV treatment has some advantages, such as decreased risks for tracheal intubation in patients with COPD, decreased rate of ventilator-associated pneumonia, and shorter hospital stays. 5 However, improper setting of NPPV parameters may negatively affect its therapeutic effect. Moreover, side-effects of NPPV, such as nasal congestion, dryness in the nasal area, facial compression, and gastric emphysema, may reduce tolerance, thereby resulting in treatment failure. HFNC continuously provides patients with regulated and relatively constant oxygen concentrations (ranging from 21% to 100%), temperature (31–37 °C), and humidity at a high flow rate (8–80 L/min) through a nasal cannula. HFNC offers good patient comfort because the high flow effectively clears nasopharyngeal dead space, increases mean airway pressure, enhances ventilation and, theoretically, improves hypoxia and hypercapnia. 6 In recent years, HFNC has gained widespread acceptance in clinical practice as a new respiratory support technology, playing a pivotal role in saving patients' lives. 7 We herein present a review of the applications of NPPV and HFNC in patients with COPD. NPPV provides positive pressure assistance without the need for invasive endotracheal intubation or tracheotomy and connects the patient to a ventilator for positive pressure-assisted ventilation using a nasal mask, orofacial mask, full-face mask, or hood. Bi-level positive airway pressure (BiPAP -Abstract Truncated-
respiratory system